{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:55:41Z","timestamp":1782129341311,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010578","name":"Deutsche Gesellschaft f\u00fcr Kardiologie-Herz und Kreislaufforschung.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020027","name":"Dr. Rolf M. Schwiete Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG SA 5419\/1-1"],"award-info":[{"award-number":["DFG SA 5419\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1550"],"award-info":[{"award-number":["CRC1550"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG VO 1659 2\/1"],"award-info":[{"award-number":["DFG VO 1659 2\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG VO 1659 2\/2"],"award-info":[{"award-number":["DFG VO 1659 2\/2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG VO 1659 4\/1"],"award-info":[{"award-number":["DFG VO 1659 4\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG VO 1659 6\/1"],"award-info":[{"award-number":["DFG VO 1659 6\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1550"],"award-info":[{"award-number":["CRC1550"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Childhood-onset cardiomyopathies are rare disease (incidence 1\/100,000) presenting with diverse, potentially severe phenotypes. The etiologies range from idiopathic\/sarcomeric forms to syndromic diseases, neuromuscular disorders, and inborn errors of metabolism, but cause-specific outcomes remain incompletely understood. This study analyzed the clinical course of a large cohort of children with hypertrophic cardiomyopathy (HCM), stratified by etiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients clinically diagnosed with HCM before 18\u00a0years of age at Heidelberg University Hospital, Germany (2000\u20132024) were included (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009146). The clinical data were compiled by the Medical Data Integration Center and supplemented by manual data extraction. Outcomes included survival, myectomy, ICD and PPM implantation, arrhythmias, heart transplantation, cardiac arrest, and echocardiographic features at first presentation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 146 patients, 31.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946) were followed into adulthood. HCM etiologies included idiopathic\/sarcomeric (37%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954), inborn errors of metabolism (21.2%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931), RASopathy (15.7%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923), neuromuscular disorders (6.8%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910), other syndromic (6.2%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099), and other (13%, n\u2009=\u200919). Diagnosis was made in infancy (&lt;\u20091\u00a0year) (47.3%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200969), childhood (1\u201318\u00a0years) (40.4%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200959), or was confirmed before age 18 without specific timing available (12.3%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918). Early diagnosis correlated with syndromic and multisystem disease. The echocardiographic findings and clinical outcomes varied by etiology. During a mean follow-up of 13.6\u2009\u00b1\u200910.5\u00a0years, 11% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) died, with 62.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) of deaths occurring within the first two years of life. Survival was highest in idiopathic\/sarcomeric HCM (96.7%) and lower in neuromuscular (85.7%), syndromic (76.2%), inborn errors of metabolism (70.5%), RASopathy (57.8%), and other forms (54.2%). Death frequently involved non-cardiovascular causes. Infants had higher early mortality, which normalized among those surviving beyond two years. In idiopathic\/sarcomeric HCM, outcomes did not differ between those diagnosed in infancy versus later childhood. Reduced ejection fraction and elevated NT-proBNP levels were predictive of mortality, while the use of Class IV anti-arrhythmics was associated with improved survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this analysis show significant variability of outcomes by HCM subtype in children. Idiopathic\/sarcomeric and neuromuscular disease-associated HCM had the best prognosis, while other non-idiopathic\/non-sarcomeric forms of HCM showed worse outcomes. Pediatric HCM presents with diverse underlying causes, unique phenotypes, and clinical trajectories, requiring tailored treatment approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02703-7","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:37:44Z","timestamp":1760366264000},"page":"795-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics and etiology-specific outcome in pediatric hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"115","author":[{"given":"Felix","family":"Minette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Klass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Merzweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Burkart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"V\u00f6lkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gorenflo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kovacevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-6582","authenticated-orcid":false,"given":"Christoph","family":"Sandmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2703_CR1","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa021715","volume":"348","author":"SE Lipshultz","year":"2003","unstructured":"Lipshultz SE, Sleeper LA, Towbin JA et al (2003) The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348:1647\u20131655","journal-title":"N Engl J Med"},{"key":"2703_CR2","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJMoa021737","volume":"348","author":"AW Nugent","year":"2003","unstructured":"Nugent AW, Daubeney PEF, Chondros P et al (2003) The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 348:1639\u20131646","journal-title":"N Engl J Med"},{"key":"2703_CR3","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/eurheartj\/ehab148","volume":"42","author":"NA Marston","year":"2021","unstructured":"Marston NA, Han L, Olivotto I et al (2021) Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J 42:1988\u20131996. https:\/\/doi.org\/10.1093\/eurheartj\/ehab148","journal-title":"Eur Heart J"},{"key":"2703_CR4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/eurheartj\/ehae109","volume":"45","author":"JP Kaski","year":"2024","unstructured":"Kaski JP, Norrish G, GimenoBlanes JR et al (2024) Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European society of cardiology EURObservational research programme cardiomyopathy and myocarditis registry. Eur Heart J 45:1443\u20131454. https:\/\/doi.org\/10.1093\/eurheartj\/ehae109","journal-title":"Eur Heart J"},{"key":"2703_CR5","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000000682","volume":"140","author":"SE Lipshultz","year":"2019","unstructured":"Lipshultz SE, Law Yuk M, Asante-Korang A et al (2019) Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American heart association. Circulation 140:e9\u2013e68. https:\/\/doi.org\/10.1161\/CIR.0000000000000682","journal-title":"Circulation"},{"key":"2703_CR6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/S0140-6736(13)61685-2","volume":"382","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Orav EJ, Wilkinson JD et al (2013) Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the pediatric cardiomyopathy registry. Lancet 382:1889\u20131897. https:\/\/doi.org\/10.1016\/S0140-6736(13)61685-2","journal-title":"Lancet"},{"key":"2703_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.106.621185","volume":"115","author":"SD Colan","year":"2007","unstructured":"Colan SD, Lipshultz SE, Lowe AM et al (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children. Circulation 115:773\u2013781. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.621185","journal-title":"Circulation"},{"key":"2703_CR8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/eurheartj\/ehy798","volume":"40","author":"G Norrish","year":"2019","unstructured":"Norrish G, Field E, Mcleod K et al (2019) Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J 40:986\u2013993. https:\/\/doi.org\/10.1093\/eurheartj\/ehy798","journal-title":"Eur Heart J"},{"key":"2703_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","volume":"14","author":"KA Rauen","year":"2013","unstructured":"Rauen KA (2013) The RASopathies. Annu Rev Genomics Hum Genet 14:355\u2013369","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"2703_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ehf2.14637","volume":"11","author":"O Boleti","year":"2024","unstructured":"Boleti O, Norrish G, Field E et al (2024) Natural history and outcomes in paediatric RASopathy-associated hypertrophic cardiomyopathy. ESC Hear Fail 11:923\u2013936. https:\/\/doi.org\/10.1002\/ehf2.14637","journal-title":"ESC Hear Fail"},{"key":"2703_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ppedcard.2018.08.009","volume":"51","author":"G Norrish","year":"2018","unstructured":"Norrish G, Elliott PM (2018) Cardiomyopathies in children: mitochondrial and storage disease. Prog Pediatr Cardiol 51:16\u201323. https:\/\/doi.org\/10.1016\/j.ppedcard.2018.08.009","journal-title":"Prog Pediatr Cardiol"},{"key":"2703_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/archdischild-2021-322455","volume":"107","author":"G Norrish","year":"2022","unstructured":"Norrish G, Rance T, Montanes E et al (2022) Friedreich\u2019s ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study. Arch Dis Child 107:450\u2013455. https:\/\/doi.org\/10.1136\/archdischild-2021-322455","journal-title":"Arch Dis Child"},{"key":"2703_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0140-6736(99)06187-5","volume":"355","author":"AJ Marian","year":"2000","unstructured":"Marian AJ (2000) Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 355:58\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(99)06187-5","journal-title":"Lancet"},{"key":"2703_CR14","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/2047487317702519","volume":"24","author":"G Norrish","year":"2017","unstructured":"Norrish G, Cantarutti N, Pissaridou E et al (2017) Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. Eur J Prev Cardiol 24:1220\u20131230. https:\/\/doi.org\/10.1177\/2047487317702519","journal-title":"Eur J Prev Cardiol"},{"key":"2703_CR15","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/S0735-1097(99)00421-0","volume":"34","author":"\u00d6-S Ingegerd","year":"1999","unstructured":"Ingegerd \u00d6-S, G\u00f6ran W, Tomas R (1999) A cohort study of childhood hypertrophic cardiomyopathy. JACC 34:1813\u20131822. https:\/\/doi.org\/10.1016\/S0735-1097(99)00421-0","journal-title":"JACC"},{"key":"2703_CR16","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2015.1855","volume":"72","author":"F Pousset","year":"2015","unstructured":"Pousset F, Legrand L, Monin M-L et al (2015) A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia. JAMA Neurol 72:1334\u20131341. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1855","journal-title":"JAMA Neurol"},{"key":"2703_CR17","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR et al (2023) 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European society of cardiology (ESC). Eur Heart J 44:3503\u20133626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","journal-title":"Eur Heart J"},{"key":"2703_CR18","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1002\/ehf2.13573","volume":"8","author":"G Norrish","year":"2021","unstructured":"Norrish G, Kolt G, Cervi E et al (2021) Clinical presentation and long-term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. ESC Hear Fail 8:5057\u20135067. https:\/\/doi.org\/10.1002\/ehf2.13573","journal-title":"ESC Hear Fail"},{"key":"2703_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2024.10.002","author":"CM Wolf","year":"2024","unstructured":"Wolf CM, Zenker M, Boleti O et al (2024) Impact of MEK inhibition on childhood RASopathy-associated hypertrophic cardiomyopathy. JACC Basic to Transl Sci. https:\/\/doi.org\/10.1016\/j.jacbts.2024.10.002","journal-title":"JACC Basic to Transl Sci"},{"key":"2703_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00431-023-05263-y","volume":"183","author":"C Saint-Laurent","year":"2024","unstructured":"Saint-Laurent C, Mazeyrie L, Yart A, Edouard T (2024) Novel therapeutic perspectives in Noonan syndrome and RASopathies. Eur J Pediatr 183:1011\u20131019. https:\/\/doi.org\/10.1007\/s00431-023-05263-y","journal-title":"Eur J Pediatr"},{"key":"2703_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijcard.2023.03.010","volume":"380","author":"LE Scheffers","year":"2023","unstructured":"Scheffers LE, Kok R, van den Berg LE et al (2023) Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease. Int J Cardiol 380:65\u201371. https:\/\/doi.org\/10.1016\/j.ijcard.2023.03.010","journal-title":"Int J Cardiol"},{"key":"2703_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIR.0000000000001151","volume":"148","author":"C Bogle","year":"2023","unstructured":"Bogle C, Colan SD, Miyamoto SD et al (2023) Treatment strategies for cardiomyopathy in children: a scientific statement from the American heart association. Circulation 148:174\u2013195. https:\/\/doi.org\/10.1161\/CIR.0000000000001151","journal-title":"Circulation"},{"key":"2703_CR23","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jamacardio.2019.2861","volume":"4","author":"G Norrish","year":"2019","unstructured":"Norrish G, Ding T, Field E et al (2019) Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids). JAMA Cardiol 4:918\u2013927. https:\/\/doi.org\/10.1001\/jamacardio.2019.2861","journal-title":"JAMA Cardiol"},{"key":"2703_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJM200107053450104","volume":"345","author":"A Frustaci","year":"2001","unstructured":"Frustaci A, Chimenti C, Ricci R et al (2001) Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy. N Engl J Med 345:25\u201332","journal-title":"N Engl J Med"},{"key":"2703_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K et al (2016) Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med 375:545\u2013555","journal-title":"N Engl J Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02703-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:55:46Z","timestamp":1776236146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2703"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02703-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study has been approved by the local ethics committee (Heidelberg University, S-762\/2023) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}